MOH

Molina Healthcare, Inc. MOH is set to report its second-quarter 2026 results on July 22, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $1.37 per share on revenues of $10.9 billion. The second-quarter earnings estimate remained stable over the past 60 days. The bottom-line projection indicates a year-over-year decrease of 75%. The Zacks Consensus Estimate for quarterly revenues suggests a year-over-year decline of 4.8%. Image Source: Zacks Investment Research For the current year, the Zacks Consensus Estimate for Molina Healthcare’s revenues is pegged at $44.4 billion, implying a fall of 2.2% year over year. Also, the consensus mark for current-year EPS is pegged at $5.23 per share, indicating a 52.6% year-over-year decline. MOH missed the consensus estimate for earnings in three of the last four quarters and beat once, with the average surprise being negative 186%. Molina Healthcare, Inc price-eps-surprise | Molina Healthcare, Inc Quote Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that’s not the case here. MOH currently has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. The Zacks Consensus Estimate for MOH’s second-quarter premium revenues from Medicaid business indicates a 1.6% increase from the prior-year quarter’s reported figure, whereas our model predicts 4.5% growth. Similarly, the consensus mark for premium revenues from the Medicare unit signals a 1.2% increase from a year ago. The consensus mark for the Marketplace’s Medical Care Ratio (MCR) is pegged at 84.89% for the to-be-reported quarter, improving from 85.40% a year ago. Our model estimate for total operating expenses indicates a 0.8% year-over-year decline. However, the consensus mark for premium revenues from the Marketplace business implies a 46.4% decrease from the year-ago quarter. The consensus mark for Molina Healthcare’s total membership is pegged at 5 million, indicating a decline from 5.8 million a year ago. Meanwhile, the consensus mark for Medicare’s MCR is pegged at 93.69% for the to-be-reported quarter, deteriorating...

The healthcare giant posts better-than-expected second-quarter earnings and hikes its full-year guidance.

Elevance Health topped Q2 earnings estimates Wednesday, despite falling medical membership, but profit was boosted by one-time "below-the-line" factors and the full-year outlook was underwhelming. ELV stock tumbled, making it among the S&P 500's early laggards. Molina Healthcare, another S&P 500 managed care stock, joined Elevance among the biggest laggards in pre-market trading.

Investing.com -- Elevance Health’s Health Benefits operating profit collapsed in the second quarter of 2026, igniting a broad premarket selloff across the managed-care sector even as the insurer’s headline earnings handily beat estimates and full-year guidance was lifted. Elevance shares are down 6.7% in premarket trade Thursday after the report showed adjusted operating margin fell to 3.6% from 5.0% year-over-year. UnitedHealth Group, which reports its own Q2 results Thursday, saw its shares fall 2.7% in premarket trading, with investors bracing that Elevance’s Medicaid margin deterioration may prove sector-wide rather than company-specific. Molina Healthcare, a pure-play Medicaid insurer, dropped as much as 9% in premarket — the steepest decline among major sector peers — bringing it sharply back from its 52-week high of $244.89 reached as recently as Tuesday’s session. Humana declined roughly 1.7% in premarket, while Centene and CVS Health fell 4.9% and 2.3%, respectively. Elevance posted Q2 2026 revenue of $50.47 billion, up 2.1% year-on-year and beating analyst consensus by 3.9%, while adjusted EPS of $7.45 came in roughly 20% above the $6.21 consensus estimate. Full-year adjusted EPS guidance was raised to at least $27.00. On the surface, those numbers look strong. Beneath them, the picture is considerably more troubling. The headline EPS figure was materially supported by an $0.80 per-share below-the-line benefit that flattered the reported result. Strip that out, and the core insurance business is under significant pressure. The Health Benefits segment, Elevance’s largest, saw operating profit fall nearly half versus the prior year as lagging Medicaid reimbursement rates and an ongoing Medicare Advantage portfolio repositioning squeezed margins. Management had previously guided investors to treat 2026 as a "trough year" for the segment, and the Q2 data validates that warning. With Elevance’s non-recurring below-the-line support and front-loaded profitability, consensus implies a steep deceleration in core earnings power through the second half. Sell-side analysts project revenue to decline 2.3% over the next 12 months, a sharp contrast to the revenue growth posted in Q2. Membership has also been gradually contracting, with the customer base slipping to 44.95 million in Q2 from 45.42 million the prior quarter, even as revenue per member has risen. Pri...

Elevance Health beat estimates for earnings and medical cost ratio, but that wasn’t enough to outweigh concerns about high Medicaid spending.

UnitedHealth Group Incorporated UNH is set to report second-quarter 2026 results on July 16, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $4.84 per share on revenues of $110.05 billion. Second-quarter earnings estimates witnessed one downward revision and no upward movement over the past 60 days. The bottom-line projection indicates an increase of 18.6% from the year-ago reported number. But the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year decline of 1.4%. Image Source: Zacks Investment Research For the current year, the Zacks Consensus Estimate for UnitedHealth’s revenues is pegged at $443.74 billion, implying a decline of 0.9% year over year. However, the consensus mark for current-year earnings per share is pegged at $18.32, implying an improvement of 12.1% on a year-over-year basis. UnitedHealth beat the consensus estimate for earnings in three of the last four quarters and missed once, with the average surprise being 0.8%. This is depicted in the figure below. UnitedHealth Group Incorporated price-eps-surprise | UnitedHealth Group Incorporated Quote Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That’s not the case here. UNH currently has an Earnings ESP of 0.00% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for premium revenues for the second quarter indicates a 2.2% year-over-year decline, whereas our model estimate suggests a 3.1% fall. Lower contributions from both the UnitedHealthcare division and Optum Health are expected to have caused the decrease. The Zacks Consensus Estimate for UnitedHealthcare’s total domestic commercial customers suggests a 1.5% year-over-year decline, whereas our estimate implies a 1.6% slip. The consensus mark for Medicare Advantage members indicates an 11% year-over-year decrease. The same for Medicaid memberships implies a 6.5% fall from the year-ago level. These are likely to have pushed total memberships in the domestic market down from the year-ago period....

Centers for Medicare & Medicaid Services released the final 2025 numbers for its risk adjustment program on Tuesday. For Molina, the firm sees a minor negative impact. Baird estimates that Molina faces an additional $11.2 million in payments beyond what it had already set aside. Shares of Centene (CNC) and Oscar Health (OSCR) closed 6% and 12% higher, respectively, on Wednesday following a note from Baird that the latest government risk adjustment settlement came in better than expected for both companies. Baird said the outcomes from the final 2025 healthcare exchange risk adjustment transfers support Centene’s prior Q4 commentary and align directionally with Oscar’s comments at a June investor conference. For Molina, the firm sees only a minor negative impact. See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox Shares of Molina (MOH) closed 2% higher on Wednesday. On June 30, the Centers for Medicare & Medicaid Services released the final 2025 numbers for its risk adjustment program. This program shifts money between health insurers in the individual market. Insurers whose customers are sicker than average receive payments from those whose customers are healthier and these payouts can swing insurers’ earnings. The June 30 report gave the final settlement using complete yearly data. Baird estimates that Molina faces an additional $11.2 million in payments beyond what it had already set aside. As for Centene, the company had already taken a large negative adjustment earlier in 2025 based on preliminary data, revising its expected headwind to roughly $2.4 billion pretax for the full year. Oscar, meanwhile, increased its risk adjustment payable accrual by about $275 million because its members appeared healthier than the broader market average in its Q4 2025 earnings. On Stocktwits, retail sentiment around CNC, MOH, and OSCR stayed within the ‘neutral’ territory at the time of writing. According to data from Koyfin, CNC has a 12-month average price target of $61.83, representing a potential downside of about 10% from the last closing price, while OSCR has an average price target of $22.60, implying a potential downside of 29%. While CNC has gained 66% year-to-date, OSCR has added 122%. Read More: TMDX Stock Rallies As Analyst Sees 77% Upside — Here’s Why For updates and corrections,...

LONG BEACH, Calif., June 02, 2026--(BUSINESS WIRE)--Molina Healthcare, Inc. (NYSE: MOH) today announced it will issue its earnings release for the second quarter ending June 30, 2026, after the market closes on Wednesday, July 22, 2026, and will host a conference call and webcast to discuss the earnings release on Thursday, July 23, 2026, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 8631129. A telephonic replay of the conference call will be available through Thursday, July 30, 2026, by dialing (855) 669-9658 and entering the confirmation number, 6469068. A live broadcast of Molina Healthcare’s conference call will be available on the Company’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available shortly following the conclusion of the live broadcast. About Molina Healthcare Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit MolinaHealthcare.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260602026473/en/ Contacts Investor Contact: Jeffrey Geyer, [email protected], 305-317-3012Media Contact: Caroline Zubieta, [email protected], 562-542-1845

It has been about a month since the last earnings report for Molina (MOH). Shares have added about 3.8% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Molina due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Molina Healthcare, Inc before we dive into how investors and analysts have reacted as of late. MOH Q1 EPS Tops Estimates on Lower Medical Costs, Membership DeclinesMolina Healthcare reported first-quarter 2026 adjusted earnings per share (EPS) of $2.35, which beat the Zacks Consensus Estimate of $1.57. The bottom line declined 61.3% from the year-ago period's level. Revenues amounted to $10.8 billion, which decreased 3.1% year over year. The top line marginally missed the consensus mark by 0.2%.The first-quarter performance was supported by lower medical care costs, partially offset by declining premiums, membership and investment income. Premium revenues of $10.2 billion decreased 4.3% year over year in the quarter under review and missed the Zacks Consensus Estimate by 0.2%. The decline was due to reduced memberships, reflecting product and pricing decisions. As of March 31, 2026, total membership decreased 12.5% year over year to around 5 million and missed the Zacks Consensus Estimate by 1.2%. The health insurer witnessed a year-over-year decrease in customers across all segments, especially in Marketplace and Other.Investment income fell 9.3% year over year to $98 million. It missed the Zacks Consensus Estimate of $100.8 million.Total operating expenses were $10.71 billion, flat year over year and slightly below our model estimate of $10.72 billion, driven by lower medical care costs. The adjusted general and administrative expense ratio increased to 6.9% in the first quarter from 6.3% a year ago. Interest expenses of $54 million rose from $43 million in the prior year.The consolidated medical care ratio (medical costs as a percentage of premium revenues), or MCR, was 91.1% in the reported quarter. It rose from 89.2% a year ago but was below the Zacks Consensus Estimate of 91.5%.Molina Healthcare’s adjusted net income decreased 64% year over year to $120 million. Molina Healthcare exited the first quarter with cash and cash equiv...

Select Medical Holdings Corporation SEM reported first-quarter 2026 adjusted earnings per share (EPS) of 36 cents, which missed the Zacks Consensus Estimate by 16.3%. The bottom line declined 18.2% year over year. Net operating revenues advanced 5% year over year to $1.4 billion. The top line beat the consensus mark by 1.5%. The quarterly earnings suffered due to an elevated expense level and a decline in patient days, exerting pressure on profitability in the Critical Illness Recovery Hospital segment. However, the downside was partially offset by solid revenue growth in the Rehabilitation Hospital segment, driven by higher admissions and improved occupancy. Select Medical Holdings Corporation price-consensus-eps-surprise-chart | Select Medical Holdings Corporation Quote Total costs and expenses were $1.3 billion, which increased 6.7% year over year and came higher than our estimate by 1.4%. The year-over-year rise was due to higher costs of services, exclusive of depreciation and amortization, and general and administrative expenses. Adjusted EBITDA declined 6.5% year over year to $141.6 million but beat our estimate of $141.1 million. The segment recorded revenues of $638.8 million in the first quarter, which grew 0.3% year over year, but missed the Zacks Consensus Estimate and our estimate of $671.3 million. The unit benefited on the back of a 1% year-over-year increase in admissions and a 2.5% rise in revenue per patient day. Patient days slipped 2.2% year over year. The occupancy rate deteriorated 140 bps year over year to 72%. Adjusted EBITDA declined 15.3% year over year to $73.4 million and fell short of the consensus mark and our estimate of $88.7 million. The adjusted EBITDA margin of 11.5% deteriorated 210 bps year over year. SEM’s Rehabilitation Hospital segment remained the primary growth engine. The unit’s revenues rose 14.5% year over year to $351.9 million, which surpassed the Zacks Consensus Estimate and our estimate of $320.8 million. The favorable performance stemmed from year-over-year increases of 13% and 12.5%, respectively, in admissions and patient days. The occupancy rate was 83%, which improved 120 bps year over year in the quarter under review. Adjusted EBITDA improved 15.1% year over year to $81.1 million, which beat the consensus mark and our estimate of $69.4 million. The adjusted EBITDA margin of 23% improved 10 bps year over...

Acadia Healthcare Company, Inc. ACHC reported adjusted first-quarter earnings of 37 cents per share, which beat the Zacks Consensus Estimate of 28 cents. However, the bottom line declined 7.5% year over year. Total revenues increased 7.6% year over year to $828.8 million. The top line beat the consensus mark of $824 million. The better-than-expected quarterly results were driven by increased patient days and revenues per patient day, and higher admissions, which were partially offset by lower average length of stay and higher expenses. Acadia Healthcare Company, Inc. price-consensus-eps-surprise-chart | Acadia Healthcare Company, Inc. Quote ACHC’s top line benefited most from its Acute Inpatient Psychiatric Facilities business, where revenues increased 14% year over year to $470.7 million and beat the Zacks Consensus Estimate by 6.4%. The metric benefited from higher volumes, aided by expanded capacity from both new construction and additions at existing facilities. Specialty Treatment Facilities’ revenues declined 6.5% from the prior-year period to $128.1 million. Comprehensive Treatment Facilities’ revenues rose 2.5% year over year to $140.4 million, while Residential Treatment Facilities’ revenues increased 6.3% to $89.6 million. Same-facility revenues of $813.4 million rose 7.3% year over year and beat the Zacks Consensus Estimate by 2%. The year-over-year improvement was driven by a 1.6% increase in patient days. Admissions grew 6.5% year over year. The average length of stay declined 4.6% year over year and missed the consensus estimate by 5.5%. Revenue per patient day increased 5.6% year over year. In the overall facility, patient days improved 1.5% year over year, while admissions grew 7.8%. Revenue per patient day increased 5.9% year over year. The average length of stay declined 5.8% year over year. Total expenses of $817.8 million rose from $757 million in the prior-year period due to higher salaries, wages and benefits, other operating expenses, supply costs and professional fees. Total adjusted EBITDA rose 7.5% year over year to $144.2 million. During the quarter, the company added 82 newly licensed beds, including 42 beds at existing facilities and 40 beds from newly constructed facilities, including a joint venture with Tufts Medicine. Acadia Healthcare exited the first quarter with cash and cash equivalents of $158.5 million, which increased...

Humana Inc. HUM reported first-quarter 2026 adjusted earnings of $10.31 per share, which beat the Zacks Consensus Estimate by 3.5%. However, the bottom line fell 11% year over year. Revenues improved 23.5% year over year to $39.6 billion. The top line surpassed the consensus mark by 0.5%. The quarterly results benefited on the back of premium gains and a robust performance from the CenterWell segment, which saw a revenue jump supported by its primary care business. A rise in overall medical membership also contributed to the upside. However, the upside was partly offset by escalating operating expenses and a deteriorating benefit ratio. Humana Inc. price-consensus-eps-surprise-chart | Humana Inc. Quote Humana’s premiums totaled $37.7 billion, which advanced 23.6% year over year, and surpassed the Zacks Consensus Estimate of $37.3 billion and our estimate of $36.6 billion. Services revenues rose 25.7% year over year to $1.7 billion, beating the consensus mark of $1.6 billion. Investment income of $262 million fell 0.8% year over year in the quarter under review. However, the metric beat the consensus mark of $230 million and our estimate of $235.7 million. The benefit ratio came in at 89.4%, which deteriorated 240 basis points (bps) year over year. Total operating expenses increased 25.9% year over year to $37.9 billion, higher than our estimate of $36.6 billion. The year-over-year increase was due to higher benefits and operating costs. The adjusted operating cost ratio of 10% improved 50 bps year over year. HUM’s net income declined 4.7% year over year to $1.2 billion but beat our estimate of $1.1 billion. The segment’s revenues rose 23% year over year to $38.1 billion in the first quarter on the back of improved per-member premiums derived from HUM’s Medicare and stand-alone PDP businesses, supported by improved Medicare Advantage benchmark funding from the Centers for Medicare and Medicaid Services and a higher Part D direct subsidy tied to the IRA. Adjusted operating income dropped 8.8% year over year to $1.4 billion. The benefit ratio deteriorated 200 bps year over year to 89.4%. The operating cost ratio of 7.3% improved 90 bps year over year. Total medical membership of the segment was 17.7 million as of March 31, 2026, which rose 19.4% year over year. The metric beat the Zacks Consensus Estimate of 16.7 million and our estimate of 15.7 million. The un...